3.2. In vitro BNZ resistance profile
Inhibitory concentrations 50 and 90 (IC50 and IC90, respectively) are shown in Figure 2 . BNZ showed higher activity against the parasite forms relevant to human infection (intracellular amastigotes and trypomastigotes). The infection rate, the average number of amastigote forms per Vero cell and the infectivity index were also determined (Figure 3A-3B ), giving and idea of the killing rate. It is widely known that the parasitic cure as soon as possible after infection can prevent parasite reproliferation and serious disease (Rao et al. , 2019). This topic has been notably supported, especially after the failure of the lastest candidates – posaconazole and ravuconazole – in clinical trials (Molina et al. , 2014; Martín-Escolano et al. , 2020a). BNZ is a fast-acting and cidal drug, and that is why here we observed a significant reduction in the infectivity index to practically zero at 50 μM.